{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Antigen[C268]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT02542462: Phase 4 Interventional Completed Intussusception
(2015)
Source URL:
First approved in 2006
Source:
BLA125122
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02542462: Phase 4 Interventional Completed Intussusception
(2015)
Source URL:
First approved in 2006
Source:
BLA125122
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02542462: Phase 4 Interventional Completed Intussusception
(2015)
Source URL:
First approved in 2006
Source:
BLA125122
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01659996: Phase 4 Interventional Completed Meningitis
(2012)
Source URL:
First approved in 2005
Source:
BLA125089
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT00282295: Phase 4 Interventional Completed Acellular Pertussis
(2006)
Source URL:
First approved in 2005
Source:
BLA125089
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT00282295: Phase 4 Interventional Completed Acellular Pertussis
(2006)
Source URL:
First approved in 2005
Source:
BLA125089
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT00282295: Phase 4 Interventional Completed Acellular Pertussis
(2006)
Source URL:
First approved in 2005
Source:
BLA125089
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103666
(2002)
Source URL:
First approved in 2002
Source:
BLA103666
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103666
(2002)
Source URL:
First approved in 2002
Source:
BLA103666
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03192371: Phase 4 Interventional Withdrawn Virus Diseases
(2018)
Source URL:
First approved in 1997
Source:
BLA103334
Source URL:
Class:
STRUCTURALLY DIVERSE